For example, LILRB1 expression protected cutaneous T-cell lymphoma cells from CD3/TCR activation induced cell death (128), while in malignant B cells LILRB1 engagement dampened tumor cell proliferation and induced cell cycle blockade (132). This evidence concerns the gene LILRB1 and T-cell non-Hodgkin lymphoma.